Hepion Pharmaceuticals, Inc. (HEPA) Form SCHEDULE 13D/A — Sep 16, 2026
KI Holdings Ltd., an investment holding company whose principal is business executive Donald Kivowitz, filed a Schedule 13D/A disclosing beneficial ownership of 10,000,000 shares of Hepion Pharmaceuticals common stock, equal to 10.2% of the class. Kivowitz is deemed to own the shares solely through his relationship with KI Holdings. The stake was acquired on August 3, 2026 under a Securities Purchase Agreement dated July 31, 2026: KI Holdings paid $500,000 in a private placement for 10,000,000 shares plus an immediately exercisable warrant to purchase up to 10,000,000 additional shares at $0.06 per share, subject to a beneficial ownership limitation.
Key figures
- Gross Proceeds
- 500000
- Warrant Shares
- 10000000
- Percent Of Class
- 10.2%
- Acquisition Date
- 2026-08-03
- Warrant Exercise Price
- 0.06
- Purchase Agreement Date
- 2026-07-31
- Beneficially Owned Shares
- 10000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.